An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study.
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2017
Price : $35 *
At a glance
- Drugs Cancer vaccine MUC-1 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors Immutep Limited; Prima BioMed
- 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
- 18 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Apr 2013 New trial record